ABSTRACT
Objective: To analyze the clinicopathological characteristics of T1 breast cancer, the risk of lymph node metastasis and related prognostic factors. Methods: The National Cancer Institute Surveillance, Epidemiology and Results (SEER) database was utilized to search and screen out 73 421 female patients with T1 breast cancer from 2010 to 2015 for retrospective analysis. Logistic regression was used to assess the risk factors of lymph node metastasis. Kaplan-Meier survival analysis was used to analysis overall survival (OS) and breast cancer-specific survival (BCSS); Log-rank test and Cox risk model were used for prognostic analysis. Results: A total of 73 421 female patients were enrolled, including 61 955 (84.4%) N0 stage, 9 995 N1 stage (13.6%), 1 087 N2 stage (1.5%) and 384 N3 stage (0.5%). Patients with invasive cancer, histological grade 3, T1c stage, progesterone receptor (PR) positive and human epidermal growth factor receptor-2 (HER-2) positive were most likely to develop lymph node metastasis (all P<0.05). The median follow-up time was 55 months. The 5-year survival rate was 93.8%, and the 5-year BCSS rate was 98.2%. Cox regression analysis showed that T stage (HR=1.517, 95%CI: 1.382-1.666, P<0.01), N stage (HR=5.173, 95%CI: 4.424-6.049, P<0.01), estrogen receptor (ER) status (HR=0.774, 95%CI: 0.607-0.987, P=0.039), PR status (HR=0.745, 95%CI: 0.689-0.806, P<0.01) and subtype (HR=1.439, 95%CI: 1.078-1.478, P=0.011) were independent prognostic risk factors for the OS. Histological grade (HR=2.100, 95%CI: 1.766-2.483, P<0.01), T stage (HR=1.310, 95%CI: 1.193-1.439, P<0.01), N stage (HR=21.230, 95%CI: 17.980-25.060, P<0.01), PR status (HR=0.855, 95%CI: 0.791-0.925, P<0.01) were independent prognostic risk factors for the BCSS in T1 breast cancer. Conclusions: The lymph node metastasis rate of T1 breast cancer is low and the overall prognosis is good. Pathological type, histological grade, tumor size and subtype maybe helpful in predicting the lymph node metastasis of T1 breast cancer.
Subject(s)
Breast Neoplasms , Breast Neoplasms/pathology , Female , Humans , Lymph Nodes , Lymphatic Metastasis , Neoplasm Staging , Prognosis , Retrospective Studies , Risk FactorsABSTRACT
Objective: To investigate the effect of centrosomal protein Cep63 on the apoptosis of papillary thyroid carcinoma (PTC) cell lines TPC-1 and underlying mechanism. Methods: With collected PTC tissues and adjacent tissues, Cep63 expression was detected by RT-qPCR and its relationship with clinicopathological factors was analyzed. The experiment included negative control group (NC), low expression group (Cep63(-)) and overexpression group (Cep63(+)), and wild-type TPC-1 cells were transfected with Cep63 lentivirus. The efficiency of Cep63 was detected by western blot (WB) and qRT-PCR. Cell proliferation ability was detected by plate cloning experiment and MTT assay. Cell apoptotic rate was detected by flow cytometry, and expression levels of apoptosis-related proteins were detected by immunohistochemistry and WB. The t-test was used to compare the differences in the means between the two groups, the one-way analysis of variance was used to compare multiple groups, and the chi-square test was used to analyze the association between gene expression levels and pathological factors. Results: Compared with NC group, cell proliferation ability was significantly decreased in Cep63(-) group (3.18±0.07 vs. 2.14±0.09, t=8.54, P<0.01) and significantly increased in Cep63(+) group (3.18±0.07 vs. 3.58±0.10, t=3.21, P<0.05). Apoptotic rates in NC, Cep63 (-) and Cep63 (+) groups were respectively 3.03%±0.24%, 8.66%±0.44% and 1.17%±0.44%, and the flow cytometry showed that the low expression of Cep63 significantly increased the apoptosis TPC-1 cells (F=157.7, P<0.001). Bcl-2 protein expression levels of NC, Cep63 (-) and Cep63 (+) groups were respectively 1.07±0.03, 0.49±0.01 and 1.99±0.09, and BAX protein expression levels of three groups were respectively 0.64±0.02, 1.06±0.01 and 0.21±0.03. WB showed that the expression level of Bcl-2 decreased (F=183.2, P<0.001), while the expression level of BAX was significantly up-regulated (F=283.7, P<0.001). Conclusion: Cep63 may regulate the apoptotic process of TPC-1 cells through Bcl-2/BAX pathway and Cep63 may be a potential oncogene of PTC.
Subject(s)
Carcinoma, Papillary , Thyroid Neoplasms , Apoptosis , Carcinoma, Papillary/genetics , Cell Cycle Proteins , Cell Line, Tumor , Cell Movement , Cell Proliferation , Gene Expression Regulation, Neoplastic , Humans , Thyroid Cancer, Papillary/genetics , Thyroid Neoplasms/geneticsABSTRACT
AIM: Acute biliary pancreatitis (ABP) is a worldwide disease. The aim of this study was to investigate the clinical efficacy of early endoscopic treatment of ABP. METHODS: From 2004 to 2010, 120 inpatients (42 male, 78 female) with ABP were randomly divided into two groups, each of which contains 60 patients. Before the intervention, patients in the two groups did not show significant differences in the age, gender, APACHE-II score, CT grading and other clinical characteristics. The early intervention group was managed with endoscopic treatment within 72 h after the initial symptom, whereas no endoscopic treatment for the control group. The mortality, complication rate, hospital stay, and the costs were compared. RESULTS: Compared with the control group, the complication rate (10% vs. 26.7%, experiment group vs. control group, the same hereinafter) and the time of pain relief (2.36±1.91 d vs. 6.52±2.39 d), time of bellyache disappeared (5.95±1.81 d vs. 7.66±3.01 d), time of temperature recovery (3.74±2.06 d vs. 5.33±2.15 d), and hospital stay (18.3±4.1 d vs. 27.1±14.6 d) of the experiment group were all shortened (P<0.05). However, the mortality (1.7% vs. 10%, P>0.1), time of serum amylase recovery (3.98±2.02 d vs. 5.11±2.22 d, P>0.1), and hospital costs (P>0.1) did not show significant difference. Early endoscopic treatment can reduce the complication of ABP and shorten the hospital stay. It could be adopted as the preferred treatment for ABP in hospitals.